Common fragile sites (CFSs) are regions of profound genomic instability that have been hypothesized to play a role in cancer. The major aim of this study was to locate a fragile region associated with ovarian cancer. Differential display (DD)-PCR analysis comparing normal ovarian epithelial cultures and ovarian cancer cell lines identified pregnancy-associated plasma protein-A (PAPPA) because of its frequent loss of expression (LOE) in ovarian cancer cell lines. PAPPA is localized to human chromosome 9q32-33.1, a region associated with significant loss of heterozygosity (LOH) in ovarian tumors (>50%) and in close proximity to the FRA9E CFS. FISH analysis determined that PAPPA was contained within the distal end of FRA9E. Characterization of FRA9E determined that aphidicolin-induced instability extended over 9 Mb, identifying FRA9E as the largest CFS characterized to date. Comprehensive LOH analysis revealed several distinct peaks of LOH within FRA9E. Semiquantitative RT-PCR analysis of 16 genes contained within FRA9E indicated that genes showing LOE in ovarian tumors coincided with regions of high LOH. PAPPA displayed the most significant loss (72%). This study provides evidence to suggest that instability within FRA9E may play an important role in the development of ovarian cancer and lends further support for the hypothesis that CFSs may be causally related to cancer.
Introduction
A chromosomal fragile site is a locus that experiences nonrandom gaps or breakage when cells are cultured under appropriate conditions. Fragile sites have been categorized into two classes, rare and common, based on their relative frequency of occurrence and further subcategorized according to the specific chemicals that induce their expression. Rare fragile sites (RFSs) are observed in less than 5% of the population and inherited in a Mendelian codominant fashion. In contrast, the common fragile sites (CFSs) are present in virtually all individuals. The vast majority of the CFSs (84 of 89) are induced by aphidicolin (APC), a DNA polymerase a/d inhibitor.
Most of the molecular information about fragile sites was obtained from the cloning and characterization of several RFSs. Each of these has been associated with the expansion of unstable repeat sequences (Oberle et al., 1991; Verkerk et al., 1991; Knight et al., 1993; Jones et al., 1994; Nancarrow et al., 1994; Ritchie et al., 1994; Yu et al., 1997; Hewett et al., 1998) . For three of the 29 known RFSs, an association between expanded repeat sequences, chromosomal fragility, and a disease phenotype has been established. Trinucleotide repeat expansions at FRAXA (Xq27.3) and FRAXE (Xq28) are associated with heritable mental retardation, and similar expansions at FRA11B (11q23.3) have been implicated in a predisposition to the chromosomal deletion disorder, Jacobsen syndrome (Jones et al., 1995; Sutherland et al., 1998) .
Unlike the RFSs, the biological consequence of instability within the CFSs is unclear, as is the underlying cause of their instability. Yunis and Soreng (1984) first proposed that CFSs play a causal role in the oncogenic process. This hypothesis originated from the observation that structural anomalies documented in various cancers cytogenetically coincided with the positions of CFSs. In addition, each of the five cloned and characterized CFSs, FRA3B (3p14.2), FRA7G (7q31.2), FRA7H (7q32.3), FRA16D (16q23.2), and FRAXB (Xp22.3), has been associated with either cancer-specific chromosomal rearrangements, a region of high loss of heterozygosity (LOH) in many cancer types, sites of viral integration, and/or gene(s) showing a loss of expression (LOE) in one or more tumor types Huang et al., 1998a, b; Mishmar et al., 1998; Smith et al., 1998; Bednarek et al., 2000; Krummel et al., 2000; Mangelsdorf et al., 2000; Paige et al., 2000; Arlt et al., 2002) . However, there remains no concrete evidence of a causal relation between the genomic instability within the CFSs and the development and/or progression of cancer.
Today, ovarian cancer comprises approximately 4% of new cancer cases and 5% of cancer deaths in females, making it the most common cause of death from gynecological malignancy (Gabra and Smyth, 1997; Landis et al., 1998) . In the United States, during 2002, the estimated numbers of new ovarian cancer cases and deaths are projected to be 23,300 and 13,900, respectively (Jemal et al., 2002) . In order to identify genes important in the development of ovarian cancer, we performed differential display-PCR (DD-PCR) analysis of short-term cultured normal ovarian surface epithelial (OSE) cells versus five low-passage ovarian cancer cell lines established at the Mayo Clinic, as well as the NIH ovarian cancer cell line, OVCAR5 (Hamilton et al., 1984; Conover et al., 1998) . One of the consistently downregulated genes encodes pregnancy-associated plasma protein-A (PAPP-A), one of four proteins originally isolated in 1974 from normal human pregnancy serum and more recently described as the IGFdependent protease that cleaves insulin-like growth factor binding protein-4 (IGFBP-4) (Lin et al., 1974; Lawrence et al., 1999) . PAPPA has been localized to human chromosome 9q32-33, a region associated with a high frequency of LOH in ovarian tumors, which also contains the CFS, FRA9E (Glover et al., 1984; Silahtaroglu et al., 1993; Schultz et al., 1995) . In addition, recurrent under-representation of the chromosome arm 9q has been documented by comparative genomic hybridization (CGH) analysis (Sonoda et al., 1997) . We determined that PAPPA was situated within the distal portion of FRA9E; therefore, we fully characterized the FRA9E CFS and investigated this highly unstable chromosomal region for LOH in ovarian tumors and for LOE of genes mapped within this CFS, including PAPPA.
Results

Cloning and characterization of FRA9E
DD-PCR was performed on short-term cultures of normal OSE versus five low-passage, ovarian cancerderived cell lines generated at the Mayo Clinic and the accessible NIH cell line, OVCAR5 (Hamilton et al., 1984; Conover et al., 1998) . Partial sequence from PAPPA was recovered from this technique because of its presence in OSE, but absence from some of the cancer cell lines. A previous report had mapped PAPPA to 9q33.1, possibly close to FRA9E (9q32) (Silahtaroglu et al., 1993) . Consequently, we selected two overlapping BACs, which together contained the entirety of the PAPPA genomic sequence, and performed fluorescence in situ hybridization (FISH) on APC-induced chromosomes. Analysis of a BAC clone harboring PAPPA exons 11-22, RPCI-11.1-45A16, on 20 APC-induced metaphases determined that all 20 signals hybridized distal to the observed breakage at 9q32, positioning this BAC clone distal to the FRA9E CFS. However, FISH analysis of BAC clone RPCI-11.1-58C3, verified to contain PAPPA exons 1-10, indicated that seven of the 20 signals hybridized proximal and 13 signals hybridized distal to breakage at 9q32 (Figure 1 , Table 1 ). Therefore, the 5 0 end of PAPPA was found to lie within the distal portion of FRA9E. As these two clones are overlapping and clone 45A16 hybridized completely distal to the site of breakage, the telomeric end of FRA9E resides within clone 58C3. BAC clones positioned 1 Mb (RPCI-11.1-445L6) and 2 Mb (RPCI-11-46P18) centromeric to 58C3 hybridized both proximal and distal to the aphidicolininduced breakage/decondensation at approximately equal frequencies among the scored metaphases (Figures  1 and 2, and Table 1 ). Therefore, we continued this analysis with additional BAC clones further centromeric to 46P18. BAC clones RPCI-11.2-444K11, 430K21, and 406O23 all produced signals that were observed equally proximal and distal to the site of breakage at 9q32, even though clone 406O23 was at least 6 Mb centromeric to 58C3 (Figures 1 and 2 , and Table 1 ). Definition of the centromeric boundary of FRA9E was determined by analysis of clone RPCI-11.2-308N19. The hybridization signal for this clone was observed distal to FRA9E breakage only twice in 20 metaphases with the remaining 18 signals observed as proximal (Table 1 ). These data indicate that the centromeric edge of FRA9E is in close proximity to 308N19. A total of 11 BAC clones located in between the proximal and distal boundaries of FRA9E were examined to ascertain the distribution of breakage frequency across the region ( Figure 2 , Table 1 ). Interestingly, the majority of these clones hybridized proximal in approximately half of the metaphases and distal to the site of breakage in the other half of the metaphases. As a result of this unusual pattern of breakage, FRA9E appears to have a broad plateau of fragility rather than the typical core peak. As a result of the efforts of the Human Genome Project, we were able to construct a sequence-based contig of FRA9E. BACs assigned to the FRA9E region were obtained from the University of California at Santa Cruz (UCSC) Human Genome Project Working Draft (http://genome.ucsc.edu/, Santa Cruz, CA, USA). Fully and partially sequenced BACs were assembled using the Sequencher computer program (Version 3.1, Gene Codes Corp., Ann Arbor, MI, USA). The sequence alignment was contiguous across the established region of fragility with flanking ends, eliminating gaps present in the UCSC database near D9S1832 and D9S174/ZFP37. As a result, we are able to estimate that the distance between the most proximal and most distal BACs, which define FRA9E, extends approximately 9.8 Mb. In addition, PAPPA was found to encompass approximately 244 kb of genomic DNA, consisting of 22 exons.
Considering the exceptionally large size of FRA9E, determined by the initial analysis of lymphocytes obtained from a single individual, we chose to analyze metaphases from two additional individuals using BACs within the proposed FRA9E region. Metaphases from the first individual were hybridized with BAC clones 272G11, 45E19, and 81L14 (Figure 2 ). Although the proximal edge was similar in position, as determined by hybridization of clone 272G11, the distal end was found to be closer to clone 45E19 than clone 81L14. Clone 81L14 hybridized distal in all 20 metaphases analyzed in this individual, whereas clone 45E19, more centromeric than 81L14, hybridized twice proximal to the observed breakage with the remaining 18 metaphases showing distal hybridization. In the second individual, clone 81L14 displayed hybridization proximal (2 times) and distal (9 times) to breakage, comparable to initial findings. These results indicate that, in one of three individuals, the distal edge of fragility is positioned slightly more centromeric. However, these observations still confirm a similar size of FRA9E within three separate individuals, indicating that the unusual dimensions of this fragile site are not unique to a single individual.
LOH analysis of primary ovarian tumors
Previous studies have indicated a high frequency of LOH in ovarian cancer at 9q32 based on the analysis of only a few markers from the region (Schultz et al., 1995) . Owing to the large region of aphidicolin-induced instability determined by our FISH analysis, we sought Figure 1 Representative examples of FISH across the region of FRA9E breakage. Seven BACs across the FRA9E region are shown. Chromosomes were obtained from separate APC-treated metaphases. Presence of breakage at 9q32 was initially identified from a DAPI image. The inverted DAPI image was used for confirmation of breakage at the 9q32 locus. Hybridization signals of the biotinlabeled BACs, detected by FITC-avidin (green), are shown as occurring both proximal and distal to the breakage at FRA9E. A summary of FISH results are shown in Table 1 to achieve a more comprehensive LOH analysis of the region in ovarian cancer. Therefore, 16 microsatellite markers across FRA9E were selected for LOH analysis on 21 primary ovarian tumors (serous, stages I-III). Of these markers, 14 localized within the fragile region, while the other two markers, D9S1866 and D9S154, were positioned beyond the centromeric and telomeric boundaries of fragility, respectively ( Figure 2 ). Representative examples of LOH analysis are shown in Figure 3 . Figure 4 shows the results obtained, with the percentage of LOH ranging from 14.3 to 69%. Of the 21 samples examined, 17 tumors (81%) displayed LOH at a minimum of one marker, and the number of markers exhibiting LOH for any one tumor ranged from one to 14 markers. The marker near PAPPA, D9S177, had the highest frequency of LOH at 69%. In addition, prominent peaks of LOH were observed with D9S1832 (52.6%), D9S105 (57%), and D9S1824 (55%). Within FRA9E, a distinct depression in LOH frequency was located in the center of the fragile region at markers D9S1856 (15%) and D9S930 (18.8%).
Gene expression analysis across FRA9E
The 9.8 Mb FRA9E region was found to contain a total of 36 known genes, including PAPPA at the telomeric end. Since the expression of genes that reside within CFSs have previously been shown to be reduced or b Number of APC-induced metaphase breaks observed for breakage at 9q32. The breakage was scored as proximal (centromeric), crossing, or distal (telomeric) Figure 2 Approximately 9.8 Mb sequence-based contig for the FRA9E region. A FRA9E contig defining the proximal (centromeric) and distal (telomeric) ends is depicted. BACs analysed by FISH in 20 APC-induced metaphases (black boxes; ) and BACs scored in less than 20 APC-induced metaphases (gray boxes; ) are represented with the final counts indicated below each box as proximal/ crossing/distal. BACs spanning the fragile site (white boxes; ) are also shown. AB020869-AB020878 (represented by long white box) is a series of Genbank accession numbers for human genomic sequence. All clones are Research Genetics RPCI-11 BACs. The estimated genomic size of the region is indicated starting at the distal end (PAPPA), based upon the order the fragile site was initially characterized. The relative positions of genes and microsatellite markers analyzed in this study are provided above the gray line , we sought to investigate the expression pattern of genes across the FRA9E region. Unique primers were designed for the majority of the genes within FRA9E to analyze a panel consisting of short-term cultured, normal ovarian surface epithelium (OSE), ovarian cancer cell lines, and primary serous tumors (Table 2) . Each gene was initially checked for expression in normal ovarian epithelial brushings (data not shown). Of the 22 genes, six were not expressed in the normal ovary, including DEC1, AMBP, TNFSF8, MUSK, ACTL7A, and ACTL7B, and therefore were not examined on the complete panel of samples. Semiquantitative RT-PCR was performed for the remaining set of genes on the entire panel of tumorderived cell lines and primary tumors (stages I-IV) ( Figure 5 ). The optimal control primers that were included with the PCR reaction for each individual gene were based on the required PCR conditions for the combined primers and the relative size of the two, specific and control, products. Control primers were designed from the sequences of the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), beta-actin (ACTB), beta-2-tubulin (TUBB2), and beta-2-microglobulin (B2M) genes (Table 2) .
PAPPA had the most significant reduction of gene expression in both the cell lines and primary tumors as Tumor  198  338  134  149  228  268  136  139  147  150  167  224  235  143  146  151  157  168  174  177 PAPPA expression was found to be consistently high in multiple normal ovarian samples, including three different short-term cultured OSE and two samples of ovarian epithelial brushings (data not shown). Five genes located near the middle of the fragile site were found to be downregulated compared to expression levels in OSE. The endothelial differentiation gene 2 (EDG2), part of the lysophosphatidic acid receptor family, exhibited LOE in one of the seven cancer cell lines (14%) and nine of the 18 primary tumor samples (50%). The guanine-nucleotide binding protein, gamma 10 gene (GNG10) demonstrated a considerable decrease of expression in 57% of cancer cell lines (4/7) and 39% of primary tumors (7/18). Diminished expression of the gene encoding for the zinc-finger protein 37, ZFP37, was detected in three of the cancer cell lines (43%) and nine of the primary tumor samples (50%). EHM2 that encodes for a protein involved in cytoskeletal structure, and HPRP4P, a U4/U6-associated splicing factor gene, did not show reduction of expression in the cancer cell lines; however, these did display reduced expression in 33% (6/18) and 17% (3/18) of the primary tumors, respectively ( Figure 5 ). The remaining 10 genes displayed no LOE in either cancer cell lines or primary tumors: KLF4, IKBKAP, CTNNAL, AKAP2, TXN, ROD1, ALAD, POLE3, ATP6J, and HXB ( Figure 5 ).
Interestingly, superimposition of the LOH pattern across the FRA9E region revealed a correlation between the expression of genes and the observed frequency of LOH (Figure 4 ). For example, ROD1, the only known gene analyzed, which lies within the central LOH depression, had normal levels of expression in both the cell lines and primary tumors. In addition, the gene with the highest LOE, PAPPA, coincided with the highest peak of LOH, at the distal edge of FRA9E. Figure 3 displays representative examples of LOE associated with LOH. This figure includes examples of allelic loss consistent with loss of expression for PAPPA and GNG10, both of which are genes near the two highest peaks of LOH. Although not all samples with observed LOE had associated LOH, any sample with LOH was Figure 5 Semiquantitative RT-PCR analysis of 16 genes mapping to the FRA9E region. Each gene was tested for expression levels in OSE (N), seven tumor-derived cell lines, and 18 primary ovarian tumors. The internal control (ACTB, GAPDH, B2M, or TUBB2) used with each specific primer set is indicated. Positive (+) and negative (À) water controls are shown, along with molecular weight ladder (MW)
Characterization of FRA9E
G Callahan et al found to have decreased expression. Markers D9S1832 and D9S1824, both with a high frequency of LOH, did not have any known genes nearby that were normally expressed in the ovarian epithelium to correlate LOE with the observed LOH from these regions. Since PAPPA had the most significant LOE within the FRA9E region, real-time PCR was performed to quantitatively confirm the results observed with semiquantitative RT-PCR (Figure 6 ). Real-time PCR analysis was also performed with the ACTB gene to control for differences in the amount of RNA in each sample and for the reverse transcription efficiency. Once normalized, tumor samples were compared with OSE to determine the percentage reduction in expression. All of the ovarian cell lines were downregulated, with averages ranging from only 0.1% (OVCAR3) to 14.1% (OV202) of normal OSE expression levels (Figure 6a ). In addition, the expression levels of the primary ovarian tumor samples were significantly lower than normal with averages from 0.7% (sample 14) to 15.9% (sample 3) of OSE expression (Figure 6b) . Therefore, the quantitative expression data for PAPPA was consistent with the results obtained with semiquantitative RT-PCR.
Discussion
In this study, we sought to identify genes that are consistently downregulated during the development of ovarian cancer. DD-PCR was utilized to compare the expression of genes in short-term cultures of normal OSE to ovarian cancer cell lines. This analysis revealed numerous genes that are normally expressed in the ovarian epithelium, but displayed LOE in ovarian cancer. One of these genes encodes for PAPP-A, one of the four proteins originally isolated in 1974 from normal human pregnancy serum (Lin et al., 1974) . Even though the biological function of PAPP-A was unclear at that time, particular interest in PAPP-A had been generated because of its clinical utility as an index of placental function and a first-trimester screen for Down's syndrome (Stabile et al., 1988; Wald et al., 1996) . Recently, PAPP-A was identified as the IGFdependent protease that cleaves the 26 kDa insulin-like growth factor binding protein-4 (IGFBP-4) into two proteolytic products (Lawrence et al., 1999) . This protease activity has been detected in medium conditioned by normal human osteoblasts, but not by transformed osteoblastic cells (Durham et al., 1995) . In agreement with these findings, Northern blot analysis has displayed PAPPA expression in normal osteoblasts with a corresponding lack of expression in several osteosarcoma cell lines (Lawrence et al., 1999) . Interestingly, human fibroblasts treated with the phorbol ester tumor promoter, beta-phorbol 12,13-didecanoate, or transformed with SV40 large T antigen exhibit diminished IGFBP-4 protease activity, by induction of the PAPP-A inhibitor, proMBP (Chen et al., 2002) .
PAPPA has previously been localized to human chromosome 9q32-33, a region associated with a high frequency of LOH in ovarian tumors (Silahtaroglu et al., 1993; Schultz et al., 1995) . In addition, the 9q32 band contains the FRA9E CFS; hence, we were interested in the genomic position of PAPPA relative to this region of instability. FISH was performed on two overlapping BAC clones, each of which contained a portion of the 244 kb PAPPA gene, to determine their association with the FRA9E region. The more telomeric BAC clone, 45A16, hybridized distal to FRA9E breakage in each of the 20 scored metaphases, placing this clone distal to the FRA9E region. In contrast, the hybridization of the BAC clone immediately centromeric to 45A16, RPCI-11.1-58C3, produced a distal signal to the aphidicolininduced decondensation/breakage at FRA9E in only 13 of 20 metaphases with proximal signal in the remaining seven metaphases. Thus, BAC clone 58C3 spans some of the telomeric portion of this CFS, incorporating PAPPA within the FRA9E region.
The placement of PAPPA within the telomeric portion of FRA9E led to the complete characterization of this unstable genomic region. The centromeric boundary of FRA9E was defined with BAC clone RPCI-11.2-308N19, as this clone hybridized proximal to FRA9E breakage in 18 of 20 examined metaphases. A total of 11 BAC clones from the region were examined between RPCI-11.1-45A16 and RPCI-11.2-308N19 with the majority of these BAC clones hybridizing at approximately equal frequencies proximal and distal to the aphidicolin-induced breakage at FRA9E (Table 1) . Sequence-based assembly of the region determined that 9.8 Mb of genomic sequence is present between 308N19, near the centromeric boundary of FRA9E, and 45A16, at the telomeric end of this region (Figure 2 ). This broad region of instability was confirmed with aphidicolininduced metaphases obtained from three separate individuals. As a result, this study defines FRA9E as the largest described CFS to date.
CFSs, in contrast to the RFSs, have been observed to span broad genomic regions. FRA3B (3p14.2), the most active of the CFSs, was originally thought to span a 500 kb region Rassool et al., 1996; Wilke et al., 1996) . However, these original characterizations of FRA3B solely defined the active center of instability without full delineation of the boundaries. Recently, the complete region of instability within the FRA3B CFS has been documented to extend as much as 4 Mb . Molecular analysis of other CFSs (FRA7G, FRA7H, FRA16D, and FRAXB) has revealed that instability within these CFSs occurs over genomic regions ranging from 200 kb to 2 Mb in size (Huang et al., 1998b; Mishmar et al., 1998; Krummel et al., 2000; Arlt et al., 2002) . As FRA9E is a less active CFS relative to FRA3B, FRA16D, and FRAXB (Glover et al., 1984) , our observation that instability within FRA9E comprises more than 9 Mb suggests that there may not be a relation between the frequency of observed aphidicolin-induced decondensation/breakage that occurs within any one CFS in vitro and the size of that unstable region.
The FRA9E CFS was examined to determine the frequency of LOH across this region in a panel of primary ovarian tumors. This detailed analysis revealed that there was frequent LOH across this CFS, with the marker near PAPPA, D9S177, showing the highest frequency of loss (69%; Figure 4 ). In addition, two distinct regions of high LOH were apparent within FRA9E, emphasized by a central region of two microsatellite markers (D9S930 and D9S1856) with negligible LOH (Figure 4) . Therefore, in the midst of this high occurrence of allelic loss in ovarian cancer, there remains a relatively low frequency of LOH in the middle of FRA9E.
There are a total of 36 known genes contained within the FRA9E region. We examined the expression of 22 of these genes in brushings from normal ovarian surface epithelial cells, and found that six genes were not normally expressed in the ovarian epithelium. The comparative expression profiles of the remaining 16 genes were varied, as some genes did not demonstrate altered expression in the ovarian cancer cell lines or primary tumors ( Figure 5 ). Six genes, including PAPPA, had frequent LOE in the panel of cell lines and primary tumors. Interestingly, the genes that displayed the greatest LOE were derived from regions of high LOH, whereas one of the genes that did not show a decrease in expression localized to a region with less LOH. Not all genes within regions of high LOH displayed LOE, which emphasizes the complexity of this large region of genomic instability.
Traditionally, CFSs are characterized by the frequency that large-insert clones within those regions hybridize proximal, distal or crossing to aphidicolin-induced decondensation/breakage in 20 separate metaphases with clear, discernible breakage at that CFS. Clones that always hybridize centromeric to the region of breakage are considered proximal to that CFS, whereas clones with solely telomeric hybridization are considered distal to that CFS. Hybridization of clones both proximal and distal to CFS breakage at approximately equal frequencies typically defines the active 'center' of that CFS region. Previously characterized CFSs, which include FRA3B, FRA16D, FRA7G, FRA7H, and FRAXB, have all been found to have compact, definitive 'center' regions flanked by trailing regions with a propensity toward proximal or distal hybridization relative to the breakage. In contrast, our analysis of FRA9E shows a more extensive region of instability than observed with any other CFS, with an extremely broad active center or 'plateau' extending over 5 Mb of genomic sequence. The LOH and LOE data for FRA9E suggest that contained within this large region of instability may be two subregions of instability with a more stable middle region. These observations raise the possibility of two or more CFSs present within this genomic region. With resolution limitations of the FISH-based assay used to clone the CFSs, more than one CFS within the same chromosomal band would be cytogenetically indistinguishable from one another. If two or more CFSs were present within the region, the typical 'centers' of active fragility would effectively merge, creating a 'plateau' across the majority of the CFS. Since FISH is currently the only technique used to characterize a CFS, we are unable to directly test the possibility of the existence of more than one CFS within 9q32.
This study represents the first characterization of the FRA9E region and the first observation of altered expression of the PAPPA gene in ovarian tumors. Of the genes analyzed within the FRA9E region, PAPPA had the most significant loss of gene expression in ovarian cell lines and primary tumors, with downregulation in 100% of the samples analyzed by quantitative real-time PCR (Figure 6 ). Loss of PAPPA, as an IGFBP-4 protease or perhaps as another yet unknown function, may provide an environment for preferential tumor growth. Intriguingly, many genes within CFSs have been associated with decreased expression in various tumor types Smith et al., 1998; Tatarelli et al., 2000; Paige et al., 2001; Arlt et al., 2002; Denison et al., 2002) . Whether these genes lose expression as a result of their location within inherently unstable regions of the genome or because of a selective growth advantage within cancer cells remains to be determined. The role of PAPPA in cancer development, along with several other genes from the FRA9E region, requires further investigation.
Materials and methods
Primary ovarian tissue and ovarian cell lines
Samples of primary serous ovarian tumors were obtained from surgical specimens taken at the Mayo Clinic. Material was promptly snap-frozen and stored at À701C until the time of processing. For LOH analysis, three stage-I, one stage-II, and 17 stage-III high-grade ovarian tumors were analysed. For semiquantitative RT-PCR, six stage-I, six stage-II, four stage-III, and two stage-IV high-grade ovarian tumors were examined. All specimens were collected under approval of the Institutional Review Board.
Normal OSE cells were obtained following oophorectomy for reasons unrelated to gynecological malignancy, then used as uncultured brushings or cultured as described (Kruk et al., 1990) . Only short-term OSE cultures with epithelial morphology and uniform cytokeratin staining were utilized. OV167, OV177, OV202, OV207, and OV266 cultures were low-passage cancer cell lines established at the Mayo Clinic (Conover et al., 1998) . OVCAR-5 was an established NIH cell line (Hamilton et al., 1984) , and SKOV-3 was obtained through American Type Culture Collection (Manassas, VA, USA). All cells were maintained according to the providers' recommendations.
Selection of clones
BAC clones were selected based on their localization to the 9q32 region by The Sanger Center (Cambridge, UK), the University of California at Santa Cruz (UCSC) Human Genome Project Working Draft (Santa Cruz, CA, USA), or by a PCR-based screen of the Research Genetics CITB Human BAC DNA Library (Release IV) (Huntsville, AL, USA), using primers designed to amplify STS markers in the region. BAC DNA was isolated according to the protocol of Kirschner and Stratakis (1999) .
FISH
Lymphocyte cultures were established from 1 ml of peripheral whole blood and 9 ml of Chang Media PB (Irvine Scientific, Santa Ana, CA, USA). Cell cultures were incubated for a total of 72 h at 371C in 5% CO 2 . At 24 h prior to harvest, APC solution was added to a final concentration of 0.4 mm. Cell harvest and metaphase preparations followed standard cytogenetic techniques.
For localization, 1 mg of BAC DNA was labeled with biotin-16-dUTP (Roche Applied Science, Indianapolis, IN, USA) by nick translation, then precipitated and hybridized to APCtreated metaphase spreads according to the protocol described by Verma and Babu (1989) . The biotin-labeled probe was detected following minor modifications of the manufacturer's protocols (Ventana Medical Systems, Tucson, AZ, USA). The chromosomes were counterstained with DAPI. Hybridization signals were observed with a Zeiss Axioplan2 fluorescence microscope, and the images were digitized using the IPLab SpectrumP software (Scanalytics Inc., Fairfax, VA, USA). The position of each clone relative to FRA9E was determined by analysis of 20 APC-treated metaphases with breakage at 9q32. Assignment of a BAC clone within the FRA9E fragile site was determined by hybridization signal observed on both sides of breakage or by signal observed on the proximal (centromeric) side of breakage in one metaphase and on the distal (telomeric) side of breakage in a separate metaphase.
LOH analysis
The percent LOH was determined by analysis of 16 microsatellite markers with a minimum of 60% heterozygosity within the human population. Primers specific for each marker were tested in matched normal blood and ovarian tumor DNA obtained from 21 patients (serous, stages I-III). DNA was obtained using standard phenol-chloroform methods. The forward primer for each marker was end-radiolabeled with gP 32 ATP (10 mCi/ml) using T4 polynucleotide kinase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. PCR was completed in a 12.5 ml reaction volume, containing 50 ng of genomic DNA, 10 mm Tris-HCl, 50 mm KCl, 1.5 mm MgCl 2 , 0.3 mm each primer, 200 mm dNTPs, and 0.5 units of Taq DNA polymerase (Promega, Madison, WI, USA) or AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA, USA). After 3 (for Promega Taq) or 10 (for AmpliTaq) min of initial denaturation at 951C, amplification was performed for 30 cycles (951C for 30 s, 50-621C for 30 s, and 721C for 30 s) with a final extension cycle at 721C for 10 min. Products were denatured and electrophoresed on 6% polyacrylamide-sequencing gels containing 8 m urea. Gels were dried and autoradiographed for 16-24 h. LOH was scored by allelic imbalance, displayed through more than 50% loss of intensity of one allele in the tumor sample, in comparison with the same allele from matched normal tissue.
Semiquantitative RT-PCR
Total RNA was extracted from normal ovarian epithelial brushings, short-term cultured normal OSE, seven ovarian tumor-derived cell lines, and 18 primary serous tumors (stages I-IV) using TRIzol reagent following the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA). For each sample, 5 mg of total RNA was treated with RNase-free DNase for 30 min at 371C to eliminate genomic DNA contamination, followed by heat inactivation of the DNase at 651C. Reverse transcription of DNase-treated RNA was performed with M-MLV RT (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol.
Unique primers were designed for a subset of genes within the FRA9E region (Table 2 ) using the Oligo 6.4 software (Molecular Insights, Cascade, CO, USA), and used in a multiplex reaction with GAPDH, ACTB, TUBB2, or B2M control primers (Table 2) . RT-PCR was routinely performed in a 12.5 ml reaction volume, containing 10 mm Tris-HCl, 50 mm KCl, 1.5 mm MgCl 2 , 0.4 mm each primer, 200 mm dNTPs, and 0.5 units of Taq DNA polymerase (Promega, Madison, WI, USA). After 3 min of initial denaturation at 951C, amplification was performed for 30 cycles (951C for 30 s, 55-601C for 30 s, and 721C for 30 s) with a final extension cycle at 721C for 10 min. Levels of expression were determined by the ratios of band intensity of the target gene to the control gene within a single sample, followed by comparison relative to the normal (OSE) expression level ratio.
Real-time PCR
Unique primers were designed within the 3 0 end of PAPPA using the Oligo 6.4 software (Molecular Insights, Cascade, CO, USA), and control primers were derived from the ACTB gene (Table 2 ). All PCR reactions were performed using a LightCycler instrument (Roche Applied Science, Indianapolis, IN, USA) in a total volume of 20 ml, containing 20 mm Tris pH 8.4, 50 mm KCl, 4 mm MgCl 2 , 0.5 mm each primer, 200 mm dNTPs, 0.05% BSA, 0.3X SYBR s Green I (Molecular Probes, Eugene, OR, USA), and 0.5 units of Platinum Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA). The amplification conditions comprised an initial denaturation at 951C for 1 min and 32 cycles at 951C for 0 s, 631C for 16 s, and 721C for 20 s. At the end of the extension step for every cycle, the fluorescence of each sample was measured to allow quantification of product. Following amplification, a melting curve was obtained by heating at 201C/s to 951C, cooling at 201C/s to 631C, then slowly heating at 0.11C/s to 991C with fluorescence data collection at 0.11C intervals. Experiments were performed in triplicate.
Quantitative analysis of the data was determined through the use of LightCycler analysis software. The SYBR Green fluorescence signal of each sample was plotted against the number of cycles. The background fluorescence is removed by establishing a noise band; then the resulting threshold is used to resolve the cycle numbers that correlate inversely with the log of the initial template concentration. The crossing points are the intersections between the best-fit lines, calculated from the log-linear portion of the amplification curve, and the noise band. A standard curve was created for both PAPPA and ACTB by performing PCR on 1 : 10, 1 : 100, and 1 : 1000 dilutions of the normal sample, OSE. Fold reduction was calculated from applying the crossing points of the samples to the standard curve. The fold reduction determined for PAPPA was normalized to that of ACTB to compensate for the amount of RNA in each sample and for the reverse transcription efficiency.
